Niall O’Donnell, Ph.D., is president, CEO and co-founder of Reneo Pharmaceuticals and managing director of RiverVest Venture Partners. Niall previously served as interim chief medical officer at Lumena Pharmaceuticals, where he was central to the development and execution of the company’s clinical strategy prior to its acquisition by Shire in 2014. He also helped co-found Excaliard Pharmaceuticals and developed the company’s clinical strategy. Excaliard was acquired by Pfizer in 2011.
Prior to joining RiverVest in 2006, Niall worked at Johnson & Johnson Pharmaceutical Research and Development in San Diego. He earned his Ph.D. in biochemistry from the University of Dundee, Scotland, and an M.A. in biochemistry from Pembroke College, Oxford. He also received an M.B.A. from the Rady School of Management of the University of California, San Diego. He is board member of Amplyx Pharmaceuticals, Lyric Pharmaceuticals, Spruce Biosciences and Avalyn Pharmaceuticals.